Evidence map›Paper›PMID 40720013›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2025

In Silico Prediction and Selection of Exon-Skipping Antisense Oligonucleotide Sequences Using eSkip-Finder.

Shuntaro Chiba, Yasushi Okuno

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shuntaro ChibaRIKEN Center for Computational Science, RIKEN, Yokohama, Japan.
Yasushi OkunoRIKEN Center for Computational Science, RIKEN, Yokohama, Japan. okuno.yasushi.4c@kyoto-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the early drug development using antisense oligonucleotides (ASOs) for exon-skipping treatment, researchers identify a region with high exon-skipping efficacy for a specific target exon, through experimental screening of ASOs. To streamline this process and reduce experimental effort, various in silico tools, including those for RNA structure modeling and prediction of skipping efficacy, have been developed. Among these tools, eSkip-Finder, a web-based server, has been developed to enhance the prediction capability of in silico skipping efficacy. It predicts exon-skipping efficacy based on user-input sequences and ASO length while providing a database with the capability for ASO search. This tool aids in designing effective ASOs for exon skipping and makes these resources accessible. Here, we introduce a method for selecting an ASO sequence using eSkip-Finder.

Indexed as

Computational BiologyExonsOligonucleotides, AntisenseSoftwareComputer SimulationHumansRNA SplicingOligonucleotides, AntisenseAntisense oligonucleotidesExon skippingMachine learningSplice switching

Identifiers

PMID40720013

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.